Hepion Pharmaceuticals‘ CRV431 has a similar, or even greater effect in reducing markers of idiopathic pulmonary fibrosis (IPF) in lung tissue, compared with standard-of-care IPF treatment, the company reported. The therapy had positive results in lung tissue from an IPF patient, according to Hepion. CRV431 is a…
News
The U.S. Food and Drug Administration (FDA) and Bellerophon Therapeutics agreed on the design of Bellerophon’s Phase 3 trial to test INOpulse — inhaled nitric oxide — in people with pulmonary fibrosis (PF) who are at risk for pulmonary hypertension (PH), the company said. INOpulse is a device that…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking treatment. And federal incentives to boost treatment development for these rare diseases have primarily focused not on creating new…
The FPR-1 protein is necessary for the recruitment of immune cells, namely neutrophils and inflammatory macrophages, to the lungs where they promote pulmonary fibrosis (PF), a mouse study shows. Depletion of FPR-1 or neutrophils prevented lung fibrosis and inflammation, supporting their potential as therapeutic targets in PF. The study…
The Pulmonary Fibrosis Foundation (PFF) and Celgene, a subsidiary of Bristol-Myers Squibb, are leading a collaboration with the long-term goal of streamlining the development of targeted treatment strategies for idiopathic pulmonary fibrosis (IPF), and the identification of disease biomarkers. In the majority of cases, the cause…
Pliant Therapeutics has raised $100 million in Series C financing that will support the clinical development of PLN-74809, a candidate therapy for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), a liver disease characterized by progressive inflammation and fibrosis of the bile ducts. The funding will…
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…
A large-scale analysis of multiple genome-wide studies has identified three new gene variants — mutations in DNA sequences — associated with idiopathic pulmonary fibrosis, a study reported. Two of these genetic variants are not directly linked to fibrosis,…
Beginning on Feb. 29, Rare Disease Day, chapters from notable scientific books and clinical review articles covering rare disorders will be available free-of-charge from Elsevier. The offer runs through April 30, and aims to supports work by researchers and clinicians into a better understanding of and treatments for rare diseases, as well…
You literally can’t miss it in the news these days — millions (if not billions) of people all over the world are talking about the increasing spread of “the new (novel) Coronavirus.” According to the Center for Disease Control (CDC), the earliest cases of COVID-19 began in the city of…
